United States Patent 9,649,352: Oritavancin Composition Claims, Scope, Validity Risks and Patent Landscape

U.S. Patent No. 9,649,352 protects pharmaceutical compositions containing a specified purity level of oritavancin drug substance, including compositions with mannitol and a 2:1 drug-substance-to-excipient ratio. The patent does not broadly claim all oritavancin products. Its principal limitations are the defined impurity profile, peak-area measurement by a specified HPLC method, and, in narrower claims, particular impurity thresholds and excipient formulations.

The strongest practical protection is directed to an intravenously administered, lyophilized oritavancin product using highly purified drug substance and mannitol. A generic manufacturer could avoid literal infringement by using a different impurity profile, a different formulation, a different drug-to-excipient ratio, or a manufacturing process that produces a composition outside the claimed analytical thresholds. The risk would depend on the final composition, not merely the manufacturing process.

What does U.S. Patent 9,649,352 claim?

The independent claims divide into two related claim groups.

Claim group	Core limitation	Commercial significance
Claims 1-7	Oritavancin drug substance preparation with at least about 90% purity, or at least about 95% under claim 2	Broadest composition protection in the patent
Claims 8-15	Maximum impurity level of not more than 4.8% for impurities 2 and 10, with narrower limits in claims 9 and 10	More specific impurity-control protection

All independent claims require:

A pharmaceutical composition.
An oritavancin drug substance preparation.
One or more pharmaceutically acceptable excipients.
A defined purity or impurity limitation.

The claims do not expressly require a particular route of administration, dosage strength, vial size, reconstitution volume, or therapeutic indication.

What is the scope of independent claim 1?

Claim 1 covers a pharmaceutical composition containing oritavancin drug substance preparation with “about 90% purity or greater by peak area” relative to impurities 2 through 16, identified as peaks B through P in Figure 2.

The claim is product-focused. It does not require proof that the composition was manufactured using a particular purification process. A composition may infringe if its oritavancin material satisfies the claimed purity limitation, even if the manufacturer used a different process.

The phrase “relative to impurities 2-16” is important. It appears to define purity by reference to the chromatographic impurity profile shown in Figure 2 rather than by a generic assay for active ingredient content. A product with 95% chemical assay purity could still fall outside the claim if its relevant chromatographic impurity profile does not match the required calculation or if the relevant peaks are not present or measurable under the claimed method.

How do claims 2 through 7 narrow claim 1?

Claim	Added limitation
2	Purity of about 95% or greater by peak area
3	Excipients selected from mannitol, sorbitol, sucrose and trehalose
4	Mannitol as the excipient
5	Drug substance preparation-to-excipient ratio of 2:1 by weight
6	Purity measured by HPLC
7	Specific C18 reverse-phase HPLC system and mobile-phase composition

Claims 3 through 5 are formulation limitations. Claim 4 is particularly relevant to a commercial product using mannitol. Claim 5 creates a narrower formulation target and may be important if the marketed product uses the specified 2:1 ratio.

Claims 6 and 7 create analytical limitations. Claim 7 is narrower than claim 6 because it specifies the stationary phase and mobile phases:

C18 reverse-phase stationary phase;
Mobile phase A: phosphoric acid/water/tetrahydrofuran at approximately 1/1000/10 by volume;
Mobile phase B: phosphoric acid/water/acetonitrile/tetrahydrofuran at approximately 1/1000/1500/25 by volume;
A gradient using mobile phase B in mobile phase A.

A party assessing infringement would need to determine whether the accused composition meets the purity requirement when analyzed under the claimed method. Testing under a materially different method may not answer the literal infringement question, although method equivalence and claim construction could become disputed issues.

What do claims 8 through 15 protect?

Claims 8 through 15 provide a second claim architecture based on limits for impurity 2 and impurity 10.

Claim	Added limitation
8	Impurity 2 plus impurity 10 at not more than 4.8% by peak area
9	Maximum impurity level of not more than 3.0% by peak area
10	Impurity 2 at no more than 1.9% and impurity 10 at no more than 2.9%
11	Excipients selected from mannitol, sorbitol, sucrose and trehalose
12	Mannitol
13	Drug substance preparation-to-excipient ratio of 2:1 by weight
14	Purity measured by HPLC
15	The specified C18 HPLC method

Claim 8 appears broader than claim 10 because it sets a combined impurity ceiling, while claim 10 assigns separate limits to the two impurities. A product could satisfy the aggregate limit in claim 8 while failing claim 10 if one impurity exceeds its individual threshold.

Claims 9 and 10 may provide useful fallback positions if a court construes claim 1’s overall purity language narrowly or finds ambiguity in the “about 90%” or “about 95%” terminology.

How should the purity limitations be interpreted?

The patent’s commercial reach depends on how “purity,” “peak area,” “impurity 2,” and “impurity 10” are construed.

Purity is not necessarily potency

The claims use chromatographic peak area. That is different from:

mass purity;
active pharmaceutical ingredient assay;
microbiological potency;
residual solvent content;
water content;
endotoxin level.

A batch may meet assay specifications while failing the patent’s chromatographic purity limitation. Conversely, a high chromatographic purity result does not establish compliance with every regulatory quality attribute.

The impurity identities are figure-dependent

The claims identify impurities by reference to peaks B through P in Figure 2. This creates a product-definition issue. The parties would likely dispute whether the peaks are sufficiently characterized by:

retention time;
relative retention time;
chemical identity;
detector response;
chromatographic conditions;
reference standards;
integration parameters.

If the specification provides adequate peak assignments and reproducible testing, the figure reference can function as a valid analytical definition. If the impurity peaks are not reproducibly identifiable, a defendant could raise indefiniteness, written-description, or enablement arguments under 35 U.S.C. §§ 112(a) and 112(b).

“About” creates a measurement boundary

Claims 1 and 2 use “about 90%” and “about 95%.” The allowable tolerance would depend on the intrinsic evidence, analytical variability and specification examples. A batch reported at 89.8%, 90.1% or 94.9% could produce a claim-construction dispute, particularly where the method has integration variability.

What formulations are protected by U.S. Patent 9,649,352?

The patent protects compositions that combine the claimed oritavancin purity profile with specified excipients. The formulation hierarchy is:

Formulation feature	Claim coverage
Any pharmaceutically acceptable excipient	Claims 1, 2, 6-10, 14-15, subject to the applicable purity limitations
Mannitol, sorbitol, sucrose or trehalose	Claims 3 and 11
Mannitol specifically	Claims 4 and 12
2:1 drug substance-to-excipient ratio	Claims 5 and 13
Specific HPLC test conditions	Claims 7 and 15

The patent does not, based on the supplied claims, expressly require a lyophilized cake, intravenous administration, a particular vial, or a particular reconstitution solvent. Those features could be described in the specification or other family patents, but they are not limitations in the claims provided.

When does U.S. Patent 9,649,352 lose exclusivity?

The patent issued May 9, 2017. Its exact expiration date cannot be established from the claim text alone because U.S. patent term may depend on:

the earliest effective nonprovisional or international filing date;
continuation or divisional priority;
patent-term adjustment;
terminal disclaimers;
patent-term extension under 35 U.S.C. § 156;
disclaimer or other post-issuance events.

The nominal term is generally 20 years from the earliest effective nonprovisional filing date under 35 U.S.C. § 154. Patent-term adjustment can extend the nominal date, while a terminal disclaimer can shorten it. The controlling term data should be taken from USPTO Patent Center and the patent’s official term calculation.

FDA regulatory exclusivity is separate from patent protection. Oritavancin is a small-molecule antibacterial product, so a future generic would ordinarily proceed through an ANDA under section 505(j), not through a biosimilar application under section 351(k).

What is the FDA and Orange Book status of oritavancin?

Orbactiv is the U.S. brand product containing oritavancin, approved by FDA in 2014 for acute bacterial skin and skin-structure infections in adults caused by susceptible Gram-positive bacteria. The product is administered intravenously. The approval is associated with NDA 206334 and the marketed sponsor has changed over time through commercial asset transactions.[1]

The Orange Book is the relevant source for listed patents and FDA-recognized exclusivity associated with the approved drug product.[2] A patent can have commercial relevance without being listed in the Orange Book, but an Orange Book-listed patent can create an ANDA notice and Paragraph IV litigation pathway.

The supplied claims are composition claims and would be the type of claims potentially relevant to an approved injectable formulation. Listing status must be verified against the current Orange Book entry and patent-listing records. The claim text alone does not establish whether all claims of U.S. Patent 9,649,352 are currently listed, delisted, or subject to a pending correction.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could challenge the patent through a Paragraph IV certification if it believes the patent is invalid, unenforceable or will not be infringed by the proposed product.

The principal design-around and litigation theories are:

Purity-profile design-around

The applicant could produce oritavancin with impurity 2 or impurity 10 outside the claimed thresholds. This approach would require regulatory acceptance of the alternative impurity profile and evidence that the changed profile does not affect safety, efficacy or stability.

Excipient design-around

Claims 3, 4, 11 and 12 are limited to particular excipients. A formulation using a different pharmaceutically acceptable excipient may avoid these dependent claims, but it could still infringe the independent claims if those claims are otherwise satisfied.

Ratio design-around

A drug-substance-to-excipient ratio other than 2:1 could avoid claims 5 and 13. It would not avoid claims 1 or 8 if the independent claim limitations remain satisfied.

Analytical-method challenge

A defendant may argue that the claim does not adequately define the relevant peaks or that the HPLC method lacks sufficient reproducibility. The patent owner would likely rely on the specification, examples and chromatographic data to establish that the impurities can be measured consistently.

Invalidity defenses

Potential validity challenges include:

indefiniteness under 35 U.S.C. § 112(b);
lack of written description under § 112(a);
lack of enablement under § 112(a);
anticipation under 35 U.S.C. § 102;
obviousness under 35 U.S.C. § 103;
improper reliance on an analytical result without adequate structural characterization.

The obviousness analysis would focus on whether prior art disclosed purified oritavancin, the relevant impurities, acceptable impurity limits, and a motivation to combine the composition with the claimed excipients.

How strong is the patent estate for oritavancin?

U.S. Patent 9,649,352 is strongest against a product that replicates all of the following:

highly purified oritavancin;
the Figure 2 impurity profile;
mannitol or another listed excipient;
a 2:1 drug-substance-to-excipient ratio;
the claimed chromatographic results.

Its protection is weaker against:

an alternative excipient system;
a materially different ratio;
a composition with a different impurity profile;
a product using a different purification strategy;
a generic that can demonstrate non-infringement through validated testing.

The patent does not, based on the supplied claims, create broad protection over the oritavancin molecule itself. Core composition-of-matter protection for oritavancin would arise from earlier patents, while this patent is directed to drug-substance quality and formulation characteristics.

How does U.S. Patent 9,649,352 compare with other possible oritavancin patents?

Patent category	Protection focus	Relevance to generic entry
Composition-of-matter patents	Oritavancin molecule or core glycopeptide structure	Potentially strongest, but commonly expired earlier
Process patents	Fermentation, purification, synthesis or isolation	May create manufacturing barriers without directly covering the final product
Drug-substance purity patents	Impurity profile and chromatographic purity	Relevant where the generic matches the reference product’s quality profile
Formulation patents	Excipients, ratios, lyophilization and stability	Relevant to ANDA formulation selection
Method-of-use patents	Treatment of bacterial infections or dosing regimens	Relevant only if the proposed labeling overlaps the patented use
U.S. Patent 9,649,352	Purity-defined oritavancin compositions	Product-specific barrier focused on quality and formulation

Because the supplied claims do not include treatment methods, manufacturing steps or dosing regimens, they should not be treated as a complete representation of the oritavancin patent estate. A full freedom-to-operate review would need the entire patent family, related continuations, Orange Book records and current ownership data.

What litigation and settlement issues matter?

A Paragraph IV notice involving this patent could lead to litigation under 21 U.S.C. § 355(j)(5)(B)(iii). The principal dispute would likely concern:

Whether the proposed product meets the claimed purity profile.
Whether impurities 2 and 10 are present at the claimed levels.
Whether testing must use the exact HPLC conditions in claims 7 and 15.
Whether the proposed excipient and ratio fall within claims 3-5 or 11-13.
Whether the impurity definitions are sufficiently definite.
Whether the claims are anticipated or obvious.

A settlement could include a licensed entry date, a covenant not to sue, a manufacturing restriction, or a product-specific formulation limitation. The claim text does not establish whether litigation, a Paragraph IV notice, or a settlement has occurred.

What geographic coverage does the patent provide?

The patent provides U.S. rights only. It can block making, using, selling, offering for sale or importing the claimed composition in the United States during its enforceable term. It does not automatically block the same product in Europe, Canada, Japan or other markets.

International coverage would require separate national patents or validated European patents. Family members may have different claim scope, expiration dates, prosecution histories and opposition outcomes. A U.S. infringement finding would not determine foreign validity or infringement.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barrier is achieving consistent control over the identified oritavancin impurities at commercial scale. The patent converts a quality attribute into a product limitation. A generic manufacturer would need to manage:

impurity formation during fermentation or synthesis;
degradation during purification;
batch-to-batch chromatographic reproducibility;
impurity clearance;
stability during storage;
reconstitution and lyophilization effects;
analytical method validation.

A process that produces an equivalent impurity profile may create infringement exposure even if it differs from the originator’s process. A process that produces a materially different profile may avoid the patent but require additional regulatory justification.

Key Takeaways

U.S. Patent 9,649,352 is directed to purity-defined oritavancin pharmaceutical compositions.
Claims 1 and 8 are the principal independent claim groups.
The patent does not broadly claim oritavancin as a molecule.
Mannitol, the listed sugar and polyol excipients, and the 2:1 ratio are narrower formulation limitations.
Claims 7 and 15 impose specific HPLC testing conditions.
The principal infringement issue is whether the accused final composition satisfies the defined chromatographic purity or impurity thresholds.
Generic applicants have potential design-around options involving impurity profile, excipient selection and drug-to-excipient ratio.
The patent’s exact expiration date requires USPTO term data, including priority, patent-term adjustment and any terminal disclaimer.
Oritavancin is an FDA-approved small-molecule antibacterial marketed as Orbactiv, so generic competition would generally proceed through the ANDA pathway rather than the biosimilar pathway.
The patent should be analyzed with earlier composition-of-matter patents, process patents, formulation patents, Orange Book listings and any related continuations.

FAQs

Does U.S. Patent 9,649,352 cover all Orbactiv products?

No. The claims cover compositions satisfying specified oritavancin purity or impurity limits and, in narrower claims, particular excipients and ratios. The patent does not cover every possible oritavancin composition solely because it contains oritavancin.

Can a generic use sorbitol instead of mannitol?

Potentially. Sorbitol is expressly listed in claims 3 and 11, so it does not avoid those claims. It may avoid the mannitol-specific claims 4 and 12, but the independent purity limitations would still require analysis.

Does a different HPLC method automatically avoid infringement?

No. A different method may complicate proof of infringement, but it does not necessarily avoid a claim if the product satisfies the claimed limitation when tested under the specified method.

Is U.S. Patent 9,649,352 a biosimilar patent?

No. Oritavancin is a small-molecule drug. The relevant abbreviated pathway for a competing product is generally an ANDA, not a biosimilar application.

Can a generic launch after the patent’s nominal expiration date?

A launch also depends on other unexpired patents, regulatory exclusivity, pediatric or patent-term extensions, litigation outcomes, injunctions and any settlement agreement. Expiration of this patent alone would not establish unrestricted market entry.

References

U.S. Food and Drug Administration. (2014). Orbactiv (oritavancin diphosphate) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,649,352, pharmaceutical compositions comprising an oritavancin drug substance preparation. USPTO.
U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 9,649,352. USPTO.
U.S. Code. (2024). 35 U.S.C. §§ 102, 103, 112, 154 and 156.
U.S. Code. (2024). 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Melinta Therap	KIMYRSA	oritavancin diphosphate	POWDER;INTRAVENOUS	214155-001	Mar 12, 2021		RX	Yes	Yes	9,649,352	⤷ Start Trial	Y	Y			⤷ Start Trial
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes	9,649,352	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015289602	⤷ Start Trial
Brazil	112017000898	⤷ Start Trial
Canada	2955256	⤷ Start Trial
China	107206050	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,649,352

Which drugs does patent 9,649,352 protect, and when does it expire?

Summary for Patent: 9,649,352